

Managed Distribution Policy Disclosure

In May 2018, The Swiss Helvetia Fund, Inc. (the “Fund”), acting pursuant to an SEC exemptive order and with the approval of the Fund’s Board of Directors (the “Board”), adopted a managed distribution policy. Under that policy, as resumed by the Board and announced in November 2019, the Fund will pay a quarterly distribution stated in terms of a fixed amount of \$0.13755 per share of the Fund’s common stock, which equates to an annualized distribution rate of 6.00% based on the Fund’s net asset value of \$9.17 as of October 31, 2020. In accordance with the policy, the Fund distributed on March 31, 2021 and June 30, 2021, \$0.13755 per share to stockholders of record on March 22, 2021 and June 21, 2021.

You should not draw any conclusions about the Fund’s investment performance from the amount of the Fund’s distribution or from the terms of the Fund’s managed distribution policy. The Board reviews the Fund’s managed distribution policy periodically and may amend or terminate the managed distribution policy at any time without prior notice to Fund stockholders, which could have an adverse effect on the market price of the Fund’s shares.

With each distribution, the Fund will issue a notice to stockholders and a press release which will provide detailed information regarding the amount and composition of the distribution and other related information. The amounts and sources of distributions reported in the notice to stockholders are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. Please refer to “Federal Income Tax and Investment Transactions” under Note 5 of the Notes to Financial Statements (Unaudited) for information regarding the tax character of the Fund’s distributions. A copy of the Fund’s Section 19(a) notices is available on the Fund’s website at www.swzfund.com.

The Fund’s total return in relation to changes in net asset value is presented in the Financial Highlights.

Management Discussion and Analysis (as of June 30, 2021)

For the six-month period ending June 30, 2021, the performance of The Swiss Helvetia Fund, Inc. (the “Fund”), as measured by the change in value in the Fund’s net asset value (“NAV”), increased 8.5% in US dollars (“USD”). For the same period, the Fund’s share price performance increased 12.1% in USD. This compares with an increase of 9.9% in the Swiss Performance Index (the “Index” or the “SPI”) in USD.

Economic environment during the period under review

Global economic review

The first quarter of 2021 was again dominated by uncertainties due to Covid-19, with a renewed rise in the number of infections in many countries and a combination of new and prolonged measures to combat the virus. Hopes for an improved economic outlook were focused on mass vaccinations campaigns that were set to take place in several countries during the second quarter.

The economic environment indeed looked brighter in the second quarter. The general success of the Covid-19 vaccines’ roll outs, official policy support of the roll outs in a number of countries, and the adaptability of many firms that operated with significant Covid-19 restrictions led us to increase our forecast for global growth, with significant upgrades to the US and

Europe. We now forecast the world economy to expand by 5.9% this year before slowing to 4.5% in 2022. To put the growth outlook in context, we believe the recovery will be driven by a re-opening of the service sector, which should favor advanced economies over emerging markets. The differential is expected to be reinforced by a greater availability of vaccines and fiscal support in developed economies. Notably, this expected outcome differs significantly from the recovery from the last recession, where massive stimulus in China led emerging markets out of the global financial crisis.

In Switzerland, as expected, the easing of coronavirus restrictions has triggered a swift recovery in the domestic economy. The Federal Government’s Expert Group (SECO) has increased its GDP forecast for 2021 to +3.6 %. The Swiss economy is also expected to grow at a significantly above-average rate in 2022.

Market environment during the period under review

In the first quarter of 2021, markets shook off worries of increasing Covid-19 infection numbers and continued to rise on the back of the vaccines’ rollouts and the hopes for a stronger-than-anticipated global economic recovery in the course of the year. From mid-February, higher inflation expectations and increased bond yields led to a short sell-off in equities. However, supported by further government


stimulus and a positive economic outlook, markets recovered quickly.

In the second quarter, global equity markets, including Switzerland's, again saw strong gains. In Switzerland, large cap stocks outperformed small & mid cap stocks and defensive stocks and sectors advanced more than cyclical stocks and sectors.

However, overall, Swiss equities underperformed international peers for the full first half 2021. They increased by

9.9% as measured by the SPI in USD. For the entire first six months of the year the MSCI World, S&P 500, and MSCI Europe returned 13.5%, 16.0%, and 11.3% in USD, respectively. This comes after the SPI's increase of 13.8% in 2020. In the first half of 2021, small & mid caps, represented by the SPI Extra Index (the "SPIEX"), outperformed large caps, represented by the Swiss Market Index Total Return (the "SMIC"), by +3.2% in USD.

Swiss Performance Index for the first half 2021



Source: Schroders, Bloomberg, as of June 30, 2021. Performance measured as total return in USD. Sectors mentioned should not be viewed as a recommendation to buy/sell. Portfolio composition is subject to change over time. Investors cannot invest directly in the Index.

Performance

During the period under review, the Fund's NAV return of 8.5% was behind the Index's return by -1.4% in USD.

In terms of style, "growth" stocks significantly outperformed their "value"

counterparts. The MSCI Switzerland Growth Index increased by 18.5% over the half year, while the value pendant increased by only 8.7% (measured in CHF, as there is no USD variant available). Amongst small & mid cap stocks, the MSCI Switzerland Small & Mid Cap Growth Index

outperformed its value counterpart by 9.8%. This better performance by growth stocks as compared to value stocks was not beneficial to the Fund, which has greater exposure to value stocks and sectors. The Fund's 'value tilt' is partly a reflection of the management style of the Fund's investment adviser, but also partly the result of industry concentration rules that restrict the Fund's exposure to the heavyweight pharmaceutical sector at a level below the benchmark weight.

The Fund's size bias towards small & mid cap stocks was a small tailwind for performance. During the period under review, the small & mid cap index SPIEX returned 14.7% and outperformed the large cap index SMIC by 3.3% (in CHF).

In terms of stock picking, positive contributions came from overweights in *Logitech*, *Swatch*, *Swissquote*, *Richemont*, *SIG Combibloc*, *Sulzer*, *SFS*, *Julius Baer* and *Sonova*, as well as an underweight in

Vifor Pharma. In contrast, negative contributions came from overweights in *SoftwareOne*, *ams*, *BKW*, *Baloise*, *Zurich Insurance* and *VZ Holding*, as well as underweights in *Kühne & Nagel*, *Straumann*, *Roche* and *Sika*. The Fund's low single digit cash position also detracted from relative performance.

Overall, the Fund underperformed the benchmark by -1.4% in the first half of 2021. Its private equity positions as a whole experienced only a small change in valuation. That said, in a period where listed equities increased strongly, private equity positions overall had a negative impact of 0.2% on relative performance.

Portfolio changes

In total, there were 10 purchases and 16 sales of listed equities on a net basis in the first half of 2021, plus a sale of the privately held *Ixodes*. As of June 30, 2021, there are 42 listed companies held by the Fund and four direct private equity investments.

THE SWISS HELVETIA FUND, INC.

New Investments by the Fund

Aryzta
OC Oerlikon
Polypeptide

Additions to Existing Investments

ams
Credit Suisse
Nestlé
SIG Combibloc
Swissquote
UBS
Zurich Insurance

Positions Entirely Disposed of

DKSH
Sensirion
Ixodes

Reductions in Existing Investments

ABB
Baloise
BKW
Cembra
Geberit
Helvetia
Julius Baer
Logitech
Novartis
Partners Group
Richemont
SFS
Swiss Life
Swiss Re

The Fund established new positions in *Aryzta*, *OC Oerlikon* and *Polypeptide*.

Aryzta is an international bakery company with a leadership position in convenience bakery that offers a range of products and services for in-store bakery solutions. *Aryzta* produces a variety of foods including, among others, artisan breads, pastries, cookies, donuts, muffins and buns. We believe that *Aryzta's* sale of its North American business will allow it to focus on and improve the quality of its balance sheet. Its core business product offerings remain strong, and we believe that its new CEO can lead the firm back into profitable growth.

Oerlikon is a global technology group that aims to become a leading provider of surface solutions, advanced materials, and materials processing. *Oerlikon* engineers materials, equipment, and surfaces and provides expert services enabling customers to have high-performance products and systems with extended lifespans. Drawing on its key technological competencies and strong financial foundation, *Oerlikon* is currently sustaining mid-term growth by executing three strategic drivers: addressing attractive growth markets, securing structural growth, and expanding through targeted mergers and acquisitions. *Oerlikon* operates its business in two divisions – Surface Solutions and Polymer Processing

Solutions – and has a global footprint of more than 10,600 employees at 179 locations in 37 countries. In 2020, *Oerlikon* generated CHF 2.3 billion in sales and invested CHF 118 million in research and development. Since the beginning of 2018, *Oerlikon* has underperformed relative to the market and relative to its industry peers. We believe that this negative performance is attributable to a cyclical decline as well as company specific issues, such as bad cost management. With the appointment of a new CFO in January 2020, however, cost management has significantly improved.

The Fund participated in the IPO of the *Polypeptide* group. *Polypeptide* is the second largest global developer and manufacturer of peptides, an area of the pharmaceutical and biotechnology value chain that is showing above-average growth.

Positions were increased in a number of stocks where the Fund's investment adviser views valuation as attractive in comparison to the market or sector, such as *ams*, *Credit Suisse*, *Nestlé*, *SIG Combibloc*, *Swissquote*, *UBS* and *Zurich Insurance*.

Positions that were reduced, mainly to trim back the exposure to their original weights after strong rises, were in *ABB*, *Baloise*, *BKW*, *Cembra*, *Geberit*, *Helvetia*, *Julius Baer*, *Logitech*, *Novartis*, *Partners Group*, *Richemont*, *SFS Swiss Life*, and *Swiss Re*.

THE SWISS HELVETIA FUND, INC.


Positions in *DKSH* and *Sensirion* were entirely disposed of. *Sensirion* was sold as the Fund's investment adviser believes that its fair valuation has been reached. *DKSH* was sold due to concerns about the potential impact of Covid-19 variants in Asian markets, which are markets that we believe are core to its success.

Outlook and Investment View

The success of the Covid-19 vaccines' roll outs, official policy support of the roll outs in a number of countries, and the adaptability of many firms that operated

with significant Covid-19 restrictions has led us to increase our forecast for global growth. This enhanced forecast is led by our expectations for the US and Europe with only a minor increase in the emerging market forecast. The differential is reinforced by the greater availability of vaccines and fiscal support in the developed economies. This expected outcome differs from the recovery from the last recession, where massive stimulus in China led the emerging markets out of the global financial crisis.

Contributions to World GDP growth (y/y)




Source: Schroders Economics Group, 26 May 2021

We expect that inflation will increase in the near term, largely as a consequence of the rise in commodity prices and the rapid pace of recovery, which has created bottlenecks in some sectors of the world economy. We believe growth in 2021 will be the fastest in the 21st century, and while there is significant spare capacity, it cannot be put in place rapidly enough to

prevent short-term shortages of materials, parts, and labour. We concur with the Federal Reserve's (the "Fed") view that there will be a transitory spike in inflation. However, we are also forecasting higher inflation further out, as we anticipate that the output gap may close in several countries and regions as capacity tightens in 2022.

Recovery paths – advanced economy output gaps closing in 2022

Level of real GDP, index (100 = Q4 2019)



Source: Schroders Economics Group, 27 May 2021

Other economies are lagging behind the US, but not by much, and policymakers can expect to come under similar scrutiny in 2022. Growth in Europe is expected to receive a significant upgrade as the pace of Covid-19 vaccinations has increased, thus improving the prospects for an earlier re-opening and the avoidance of further restrictions. Inflation is also expected to rise more than originally forecast, but remains low in comparison to the US, and therefore we do not anticipate that the European Central Bank will change its current policy path.

Emerging markets (“EMs”) should benefit from a stronger global economy, but the upgrades to our forecasts are not large, and we believe GDP growth in EMs may barely exceed the pace of expansion in developed markets next year. A period of above-target inflation in many EMs should subside as the impact of higher food and energy costs fades, negating the need for aggressive interest rate hikes by most central banks.

Nonetheless, a more hawkish Fed could lead to a more challenging environment for investors with higher volatility levels. We believe this could be accompanied by an end to ultra-low interest rates and a decrease or unwinding of monetary stimuli. Put differently, while there is likely still going to be an appetite for some supportive fiscal stimuli, we believe that the sheer amount of fiscal spending throughout the Covid-19 crisis is not sustainable. In the course of Q2 2021, we again saw a significant outperformance of quality growth companies which led to valuation multiples at record levels in this segment. We expect style and sector leadership to revert more towards “reflation”. While we do not anticipate this style rotation will happen all at once, we are convinced that the Fund’s portfolio – with its focus on quality, valuation, and sustainability – is well positioned to benefit from this evolution.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets
Common Stock — 96.03%				Biotechnology — (continued)			
Banks — 4.31%				Biotechnology — (continued)			
6,469	Cembra Money Bank AG Provides financial services. The company's services include personal loans, vehicle financing, credit cards and savings and insurance services. (Cost \$384,501)	\$ 725,737	0.50%	3,788	PolyPeptide Group AG¹ Operates as a biotechnology company. The Company focuses on producing proprietary and generic GMP grade peptides for the pharmaceutical and biotechnology industry. (Cost \$266,102)	\$ 349,970	0.24%
221,000	Credit Suisse Group AG A global diversified financial services company with significant activity in private banking, investment banking and asset management. (Cost \$2,744,282)	2,317,231	1.59%			2,475,919	1.70%
212,000	UBS Group AG Provides retail banking, corporate and institutional banking, wealth management, asset management and investment banking. (Cost \$2,916,983)	3,247,601	2.22%	Building Materials — 2.97%			
		6,290,569	4.31%	660	Forbo Holding AG Produces floor coverings, adhesives and belts for conveying and power transmission. (Cost \$1,054,700)	1,250,955	0.86%
Biotechnology — 1.70%				2,100	Geberit AG Manufactures and supplies water supply pipes and fittings, installation, and drainage and flushing systems such as visible cisterns other sanitary systems for the commercial and residential construction markets. (Cost \$1,000,204)	1,576,675	1.08%
36,000	Idorsia Ltd.¹ Researches, develops, and manufactures pharmaceutical, biological, and diagnostic products. (Cost \$1,027,734)	990,794	0.68%	4,600	Sika AG Manufactures construction materials, producing concrete and mixtures, mortar, sealants and adhesives, tooling resins, anti-static industrial flooring, and acoustic materials. The company serves customers worldwide. (Cost \$667,980)	1,505,382	1.03%
1,600	Lonza Group AG Produces organic fine chemicals, biocides, active ingredients, and biotechnology products. (Cost \$1,002,069)	1,135,155	0.78%			4,333,012	2.97%

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets
Common Stock — (continued)				Diversified Financial Services — 3.52%			
Chemicals — 1.13%				31,835 Julius Baer Group Ltd.			
148,778	OC Oerlikon Corp. AG Manufactures industrial equipment. The Company produces protective coatings for precision tools and components, equipment for textile production, and propulsion technology drive systems. (Cost \$1,629,805)	\$ 1,651,390	1.13%	31,835	Julius Baer Group Ltd. Provides private banking services. The company advises on wealth management, financial planning and investments; offers mortgage and other lending, foreign exchange, securities trading, custody and execution services. (Cost \$1,344,842)	\$ 2,079,512	1.42%
				12,700 Swissquote Group Holding SA			
				Through its subsidiaries, offers online financial services. The company operates an online trading system which offers customers real-time securities quotes on the Swiss Stock Exchange. (Cost \$1,365,463)			
				1,920,766 1.32%			
Commercial Services — 0.47%							
221	SGS SA Provides industrial inspection, analysis, testing, and verification services. (Cost \$553,249)	682,354	0.47%				
				5,137,218 0.78%			
				5,137,496 3.52%			
Computers — 4.27%							
40,000	Logitech International SA Engages in the development and marketing of hardware and software products that enable or enhance digital navigation, music and video entertainment, gaming, social networking and audio and video communication. (Cost \$542,328)	4,850,976	3.32%				
58,611	SoftwareONE Holding AG Provides IT services. The Company offers cloud computing, portfolio management, procurement, unified communication, and other related solutions. (Cost \$1,249,079)	1,385,461	0.95%				
				6,236,437 4.27%			

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets
Common Stock — (continued)							
Electric — 1.27%				Food — (continued)			
17,771	BKW AG Provides energy supply services. The company focuses on the production, transportation, trading and sale of energy. In addition to energy supply, the company also develops, implements and operates energy solutions for its clients. (Cost \$1,113,645)	\$ 1,851,406	1.27%	206,000	Nestlé SA One of the world's largest food and beverage processing companies. (Cost \$14,003,625)	\$ 25,677,849	17.59%
						26,456,712	18.12%
Electronic Components & Equipment — 2.23%				Hand/Machine Tools — 0.96%			
96,000	ABB Ltd. Provides power and automation technologies. The company operates under segments that include power products, power systems, automation products, process automation, and robotics. (Cost \$2,239,882)	3,260,064	2.23%	4,550	Schindler Holding AG Manufactures and installs elevators, escalators, and moving walkways internationally. The company's products are used in airports, subway stations, railroad terminals, shopping centers, cruise ships, hotels, and office buildings. The company also offers maintenance services. (Cost \$977,749)	1,393,033	0.96%
		3,260,064	2.23%			1,393,033	0.96%
Food — 18.12%				Healthcare-Products — 4.98%			
570,477	Aryzta AG¹ Produces and retails specialty bakery products. The Company produces French breads, pastries, continental breads, confections, artisan breads, homestyle lunches, viennoiserie, patisserie, cookies, pizza, appetizers, and sweet baked goods. (Cost \$759,601)	778,863	0.53%	10,200	Alcon, Inc. Manufactures eye care products. The company produces and markets vitreoretinal and cataract surgery, contact lenses, and refractive technology products. (Cost \$667,799)	714,833	0.49%

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets
Common Stock — (continued)				Healthcare-Products — (continued)			
125,416	Eyesense AG, Series A^{1,2,3} A spin-out from Ciba Vision AG. Develops novel ophthalmic self- diagnostic systems for glucose monitoring of diabetes patients. (Cost \$3,007,048)	\$ 46,131	0.03%	5,295	Tecan Group AG Manufactures and distributes laboratory automation components and systems. The products are mainly used by research and diagnostic laboratories. (Cost \$486,487)	\$ 2,625,875	1.80%
3,500	Medacta Group SA¹ Produces and distributes medical devices. The company develops, manufactures, and distributes orthopedic and neurosurgical medical devices. (Cost \$341,248)	459,674	0.32%			7,267,164	4.98%
5,486	Sonova Holding AG Designs and produces wireless analog and digital in-the-ear and behind-the-ear hearing aids and miniaturized voice communications systems. (Cost \$846,271)	2,065,374	1.41%				
250,550	Spineart SA^{1,2,3} Designs and markets an innovative full range of spine products, including fusion and motion preservation devices, focusing on easy to implant high-end products to simplify the surgical act. (Cost \$1,761,659)	1,355,277	0.93%				
					Healthcare-Services — 0.58%		
				11,900	Galenica AG Retails pharmaceutical products, and services customers in Switzerland. The Company offers health, beauty, and related products and services. (Cost \$602,995)	840,666	0.58%
						840,666	0.58%
					Industrials — 0.91%		
				2,900	Belimo Holdings AG Manufactures heating, ventilation and air conditioning equipment. (Cost \$344,115)	1,327,095	0.91%
						1,327,095	0.91%
					Insurance — 9.17%		
				10,537	Baloise Holding AG Offers group and individual life, health, accident, liability property, and transportation insurance to customers in Europe. The Company also offers private banking and asset management services. (Cost \$1,626,589)	1,644,928	1.13%

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets
Common Stock — (continued)							
Insurance — (continued)				Metal Fabricate/Hardware — 1.25%			
14,838	Helvetia Holding AG Provides a broad range of life, casualty, liability, accident and transportation insurance in Switzerland and in other European countries. The Company insures individuals, property such as vehicles and buildings, and consumer goods and personal belongings (Cost \$1,458,102)	\$ 1,597,210	1.09%	12,700	SFS Group AG Provides automotive products, building and electronic components, flat roofing and solar fastening systems. The company operates production facilities in Asia, Europe and North America. (Cost \$846,209)	\$ 1,828,712	1.25%
						1,828,712	1.25%
Miscellaneous Manufacturing — 1.41%							
7,339	Swiss Life Holding AG Provides life insurance and institutional investment management. (Cost \$2,387,463)	3,569,659	2.44%	14,620	Stadler Rail AG Engineers and manufactures trains. The company offers suburban and regional transport trains, light rail vehicles, and trams. (Cost \$608,027)	643,416	0.44%
8,359	Swiss Re AG Offers reinsurance, insurance, and insurance linked financial market products. (Cost \$602,605)	754,919	0.52%	10,200	Sulzer AG Manufactures machinery and equipment, and operates in a surfacing technology business. The Company provides pumping and surface technology solution and services, services and repair of thermal turbo machinery, and service for separation and static mixing. (Cost \$964,564)	1,410,245	0.97%
14,500	Zurich Insurance Group AG Provides insurance-based financial services. The company offers general and life insurance products and services for individuals, small businesses, commercial enterprises, mid-sized and large corporations, and multinational companies. (Cost \$4,874,010)	5,822,903	3.99%				
						2,053,661	1.41%
		13,389,619	9.17%				

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets
Common Stock — (continued)				Private Equity — 1.81%			
Packaging & Containers — 2.27%				1,738 Partners Group Holding AG			
122,000	SIG Combibloc Group AG The company, through its subsidiaries, manufactures and produces bottling machines and systems for the food and beverage industries. The company serves customers worldwide. (Cost \$1,440,475)	\$ 3,318,094	2.27%			\$ 2,635,157	1.81%
		<u>3,318,094</u>	<u>2.27%</u>			<u>2,635,157</u>	<u>1.81%</u>
Pharmaceuticals — 24.26%				Retail — 7.00%			
182,000	Novartis AG One of the leading manufacturers of branded and generic pharmaceutical products. (Cost \$10,237,492)	16,602,196	11.37%	53,500	Cie Financiere Richemont SA Manufactures and retails luxury goods. Produces jewelry, watches, leather goods, writing instruments and men's and women's wear. (Cost \$4,052,626)	6,479,499	4.44%
49,901	Roche Holding AG Develops and manufactures pharmaceutical and diagnostic products. Produces prescription drugs to treat cardiovascular, infectious and autoimmune diseases and for other areas including dermatology and oncology. (Cost \$9,346,153)	18,816,459	12.89%	56,628	Swatch Group AG - Registered Shares Manufactures finished watches, movements and components. Produces components necessary to its various watch brand companies. The company also operates retail boutiques. (Cost \$4,903,863)	3,740,076	2.56%
		<u>35,418,655</u>	<u>24.26%</u>			<u>10,219,575</u>	<u>7.00%</u>

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

No. of Shares	Security	Value	Percent of Net Assets	No. of Shares	Security	Value	Percent of Net Assets						
Common Stock — (continued)				Limited Partnership — 0.71%									
Semiconductors — 1.44%				Biotechnology — 0.71%									
105,000	AMS AG¹ Designs and manufactures advanced sensor solutions. The company also delivers a broad range of technology solutions for consumer electronics and communication device manufactures. (Cost \$1,780,070)	\$ 2,108,292	1.44%	3,294,705	Aravis Biotech II, Limited Partnership^{1,3,4} Makes early stage venture investments in the biotechnology & pharmaceuticals industry. (Cost \$1,810,184)	\$ 1,034,053	0.71%						
		2,108,292	1.44%		Total Limited Partnership (Cost \$1,810,184)	1,034,053	0.71%						
	Total Common Stock (Cost \$91,619,040)	140,175,082	96.03%	Short-Term Investment — 0.67%									
Preferred Stock — 0.03%				U.S. Bank Money Market Deposit Account, 0.003%⁵ (Cost \$985,270)									
Industrial Goods & Services — 0.03%													
500,863	SelfFrag AG Class A^{1,2,3} Designs, manufactures and sells industrial machines and processes using selective fragmentation technology. (Cost \$1,932,198)	48,767	0.03%	Total Short-Term Investment (Cost \$985,270)									
		48,767	0.03%	Total Investments (Cost \$96,346,692)									
	Total Preferred Stock (Cost \$1,932,198)	48,767	0.03%	Other Assets									
				Less Liabilities									
				Net Assets									
				<table border="0" style="width: 100%;"> <tr> <td style="width: 60%;">Net Asset Value Per Share: (\$145,978,843 + 13,212,254 shares outstanding, \$0.001 par value: 50 million shares authorized)</td> <td style="width: 40%; text-align: right; vertical-align: bottom;">\$11.05</td> </tr> </table>				Net Asset Value Per Share: (\$145,978,843 + 13,212,254 shares outstanding, \$0.001 par value: 50 million shares authorized)	\$11.05				
Net Asset Value Per Share: (\$145,978,843 + 13,212,254 shares outstanding, \$0.001 par value: 50 million shares authorized)	\$11.05												
				<table border="0" style="width: 100%;"> <tr> <td style="width: 60%;"></td> <td style="width: 40%; text-align: right; border-top: 1px solid black;">3,735,671</td> <td style="width: 40%; text-align: right; border-top: 1px solid black;">2.56%</td> </tr> <tr> <td></td> <td style="text-align: right; border-top: 1px solid black; border-bottom: 3px double black;">\$145,978,843</td> <td style="text-align: right; border-top: 1px solid black; border-bottom: 3px double black;">100.00%</td> </tr> </table>					3,735,671	2.56%		\$145,978,843	100.00%
	3,735,671	2.56%											
	\$145,978,843	100.00%											

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(continued)

June 30, 2021

¹ Non-income producing security.

² Value determined using significant unobservable inputs.

³ Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced in accordance with the Fund's valuation policy and procedures. At the end of the period, the aggregate Fair Value of these securities amounted to \$2,484,228 or 1.70% of the Fund's net assets. Additional information on these securities is as follows:

Security	Acquisition Date	Cost
Aravis Biotech II, Limited Partnership	July 31, 2007 – May 29, 2018	\$1,810,184
Eyesense AG – Common Shares	July 22, 2010 – October 3, 2011	3,007,048
SelFrag AG – Class A – Preferred Shares	December 15, 2011 – January 28, 2014	1,932,198
Spineart SA – Common Shares	December 22, 2010 – December 20, 2020	1,761,659
		<u>\$8,511,089</u>

⁴ Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company's outstanding voting securities or an equivalent interest in the company. Details related to affiliated company holdings are as follows:

Name of Issuer	Value as of 12/31/20	Gross Additions	Gross Reductions	Realized Gain/(Loss)	Change in Unrealized Gain/(Loss)	Interest Income	Value as of 6/30/21
Aravis Biotech II, Limited Partnership	\$1,072,405	\$ —	\$ —	\$ —	\$ (38,352)	\$ —	\$1,034,053
Ixodes AG – Preferred Shares B	8,172	—	(21,882)	(2,230,260)	2,243,970	—	—
	<u>\$1,080,577</u>	<u>\$ —</u>	<u>\$(21,882)</u>	<u>\$(2,230,260)</u>	<u>\$2,205,618</u>	<u>\$ —</u>	<u>\$1,034,053</u>

⁵ Rate shown is the seven day annualized yield as of June 30, 2021.

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Schedule of Investments by Industry (Unaudited)
(concluded)

June 30, 2021

PORTFOLIO HOLDINGS

% of Net Assets as of June 30, 2021

Industry:	
Pharmaceuticals	24.26%
Food	18.12%
Insurance	9.17%
Retail	7.00%
Healthcare-Products	4.98%
Banks	4.31%
Computers	4.27%
Diversified Financial Services	3.52%
Building Materials	2.97%
Biotechnology	2.41%
Packaging & Containers	2.27%
Electronic Components & Equipment	2.23%
Private Equity	1.81%
Semiconductors	1.44%
Miscellaneous Manufacturing	1.41%
Electric	1.27%
Metal Fabricate/Hardware	1.25%
Chemicals	1.13%
Hand/Machine Tools	0.96%
Industrials	0.91%
Short-Term Investment	0.67%
Healthcare-Services	0.58%
Commercial Services	0.47%
Industrial Goods & Services	0.03%
Other Assets Less Liabilities	2.56%
	<u>100.00%</u>

TOP 10 PORTFOLIO HOLDINGS

% of Net Assets as of June 30, 2021

Nestlé SA	17.59%
Roche Holding AG	12.89%
Novartis AG	11.37%
Cie Financiere Richemont SA	4.44%
Zurich Insurance Group AG	3.99%
Logitech International SA	3.32%
Swatch Group AG - Registered Shares	2.56%
Swiss Life Holding AG	2.44%
SIG Combibloc Group AG	2.27%
ABB Ltd.	2.23%

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Statement of Assets and Liabilities (Unaudited)

June 30, 2021

Assets:

Investments in unaffiliated issuers, at value (cost \$94,536,508)	\$141,209,119
Investments in affiliated issuers, at value (cost \$1,810,184)	<u>1,034,053</u>
Total Investments, at value (cost \$96,346,692)	<u>142,243,172</u>
Foreign currency (cost \$2,297,874)	2,241,364
Tax reclaims receivable	1,747,283
Receivable for investment sold	144,732
Interest receivable	3
Prepaid expenses	<u>31,335</u>
Total assets	<u>146,407,889</u>

Liabilities:

Accrued:	
Investment advisory fees	88,423
Audit fees	27,710
Legal fees	119,707
Custody fees	19,748
Directors' fees and expenses	70,373
Other expenses	<u>103,085</u>
Total liabilities	<u>429,046</u>
Net assets	<u>\$145,978,843</u>

Composition of Net Assets:

Paid-in capital	\$101,615,444
Total distributable earnings	<u>44,363,399</u>
Net assets	<u>\$145,978,843</u>

Net Asset Value Per Share:

(\$145,978,843 ÷ 13,212,254 shares outstanding, \$0.001 par value: 50 million shares authorized)	<u>\$ 11.05</u>
---	-----------------

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Statement of Operations (Unaudited)

For the Six Months Ended June 30, 2021

Investment Income:

Dividend (less of foreign tax withheld of \$455,661)	\$ 2,582,079
Interest income	6
Total income	<u>2,582,085</u>

Expenses:

Investment advisory fees (Note 2)	488,636
Directors' fees and expenses	150,628
Officer fees	66,427
Administration fees (Note 3)	62,300
Insurance fees	54,711
Custody fees (Note 3)	45,985
Delaware franchise tax fees	40,000
Audit fees (Note 3)	27,708
Printing and shareholder reports	26,791
Transfer agency fees (Note 3)	16,798
Miscellaneous expenses	54,003
Total expenses	<u>1,033,987</u>
Net investment income	<u>1,548,098</u>

Realized and Unrealized Gains (Loss) on Investments and Foreign Currency:

Net realized gain (loss) from:	
Investments in unaffiliated issuers	4,587,205
Investments in affiliated issuers	(2,230,260)
Foreign currency translations	29,110
Total net realized gain from unaffiliated and affiliated issuers and foreign currency translations	<u>2,386,055</u>
Net change in unrealized appreciation (depreciation) from:	
Investments in unaffiliated issuers	5,562,672
Investments in affiliated issuers	2,205,618
Foreign currency translations	(128,448)
Total net change in unrealized appreciation from unaffiliated and affiliated issuers, and foreign currency translations	<u>7,639,842</u>
Net Realized and Unrealized Gain on Investments and Foreign Currency ...	<u>10,025,897</u>

Net Increase in Net Assets from Operations	<u><u>\$11,573,995</u></u>
---	----------------------------

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Statement of Changes in Net Assets

	For the Six Months Ended June 30, 2021 (Unaudited)	For the Year Ended December 31, 2020
Increase (Decrease) in Net Assets:		
Operations:		
Net investment income	\$ 1,548,098	\$ 598,464
Total net realized gain (loss) from unaffiliated and affiliated issuers and foreign currency translations ...	2,386,055	(2,132,389)
Total net change in unrealized appreciation from unaffiliated and affiliated issuers, and foreign currency translations	<u>7,639,842</u>	<u>18,557,764</u>
Net increase in net assets from operations	<u>11,573,995</u>	<u>17,023,839</u>
Distributions to Stockholders:		
From earnings	(3,634,691)	(1,066,099)
From return of capital	<u>—</u>	<u>(6,332,807)</u>
Total distributions to stockholders	<u>(3,634,691)</u>	<u>(7,398,906)</u>
Capital Stock Transactions:		
Value of shares repurchased through stock repurchase program (Note 6)	<u>(125)</u>	<u>(449,102)</u>
Total decrease from capital share transactions	<u>(125)</u>	<u>(449,102)</u>
Total increase in net assets	7,939,179	9,175,831
Net Assets:		
Beginning of period	<u>138,039,664</u>	<u>128,863,833</u>
End of period	<u>\$145,978,843</u>	<u>\$138,039,664</u>

See Notes to Financial Statements (Unaudited).

THE SWISS HELVETIA FUND, INC.

Financial Highlights

	For the Six Months Ended June 30, 2021 (Unaudited)	For the Years Ended December 31,				
		2020	2019	2018	2017	2016
Per Share Operating Performance:						
Net asset value at the beginning of period ...	\$ 10.45	\$ 9.71	\$ 7.96	\$ 14.10	\$ 11.66	\$ 12.30
Income from Investment Operations:						
Net investment income ¹	0.12	0.05	0.01	0.14	0.13	0.15
Net realized and unrealized gain (loss) on investments ²	0.76	1.24	1.88	(1.35)	2.41	(0.45)
Total from investment activities	0.88	1.29	1.89	(1.21)	2.54	(0.30)
Gain from capital shares repurchases	—	—	—	—	—	0.02
Gain from tender offer	—	—	—	0.30	0.03	—
Capital change resulting from the issuance of fund shares	—	—	—	(0.12)	—	(0.03)
Anti-dilutive effect of common share repurchase program	—	0.01	—	—	—	—
Less Distributions:						
Dividends from investment income and net realized gains from foreign currency transactions	(0.28)	(0.08)	(0.12)	(0.10)	(0.13)	(0.12)
Distributions from net realized capital gains ..	—	—	(0.02)	(5.01)	—	(0.21)
Return of Capital	—	(0.48)	—	—	—	—
Total distributions	(0.28)	(0.56)	(0.14)	(5.11)	(0.13)	(0.33)
Net asset value at end of period	\$ 11.05	\$ 10.45	\$ 9.71	\$ 7.96	\$ 14.10	\$ 11.66
Market value per share at the end of period ..	\$ 9.73	\$ 8.94	\$ 8.41	\$ 6.90	\$ 12.76	\$ 10.21
Total Investment Returns:^{3,4}						
Based on market value per share	12.09%	14.18%	24.00%	-10.90%	26.26%	-0.24%
Based on net asset value per share	8.50%	14.29%	23.80%	-6.98%	22.17%	-2.19%
Ratios to Average Net Assets:⁵						
Net expenses	1.48%	1.80%	2.13%	1.44%	1.40%	1.19%
Gross expenses	1.48%	1.80%	2.13%	1.44%	1.40%	1.19%
Net investment income	2.22%	0.48%	0.10%	1.12%	0.98%	1.26%
Supplemental Data and Ratios						
Net assets at end of period (000's)	\$145,979	\$138,040	\$128,864	\$105,577	\$356,832	\$327,861
Average net assets during the period (000's) ..	\$140,570	\$125,666	\$118,960	\$305,270	\$350,487	\$331,874
Portfolio turnover rate	6%	12%	18%	21%	9%	19%

¹ Calculated using the average shares method.

² Includes net realized and unrealized currency gains and losses.

³ Total investment return based on market value differs from total investments return based on net asset value due to changes in the relationship between the market value of the Fund's shares and its NAV per share.

⁴ Not annualized for periods less than one year.

⁵ Annualized for periods less than one year.

See Notes to Financial Statements (Unaudited).

Notes to Financial Statements (Unaudited)

Note 1—Organization and Significant Accounting Policies

A. Organization

The Swiss Helvetia Fund, Inc. (the “Fund”) is registered under the Investment Company Act of 1940, as amended (the “Act”), as a non-diversified, closed-end management investment company. The Fund is organized as a corporation under the laws of the State of Delaware.

The investment objective of the Fund is to seek long-term growth of capital through investment in equity and equity-linked securities of Swiss companies. The Fund may also acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

B. Securities Valuation

The Fund values its investments in accordance with accounting principles generally accepted in the United States (“GAAP”).

When valuing listed equity securities, the Fund uses the last sale price on the securities exchange or national securities market on which such securities primarily are traded (the “Primary Market”) prior to the calculation of the Fund’s net asset value (“NAV”). When valuing equity securities that are not listed (except privately-held companies and private equity limited partnerships) or that are listed but have not traded on a day on which the Fund calculates its NAV, the Fund uses the mean between the bid and asked prices for that day. If there are no asked quotations for such a security, the value of such security will be the most recent bid quotation on the Primary Market on that day. On any day when a security’s Primary Market is closed because of a local holiday or other scheduled closure, but the New York Stock Exchange is open, the Fund may use the prior day’s closing prices to value such security regardless of the length of the scheduled closing.

When valuing fixed-income securities, if any, the Fund uses the last bid price prior to the calculation of the Fund’s NAV. If there is no current bid price for a fixed-income security, the value of such security will be the mean between the last quoted bid and asked prices on that day. Overnight and certain other short-term fixed-income securities with maturities of less than 60 days will be valued by the amortized cost method, unless it is determined that the amortized cost method would not represent the fair value of such security.

It is the responsibility of the Fund’s Board of Directors (the “Board”) to establish procedures to provide for the fair valuation of the Fund’s portfolio holdings. When valuing securities for which market quotations are not readily available, or for which the market quotations that are available are considered unreliable, the Fund determines a fair value in good faith in accordance with these procedures (a “Fair Value”). The Fund may use these procedures to establish the Fair Value of securities when, for example, a significant event occurs between the time the market closes and the time the Fund values its investments. After consideration of various factors, the Fund may value the securities at their last reported price or at some other value.

Swiss exchange-listed options, if any, including Eurex-listed options, are valued at their most recent sale price (latest bid for long options and the latest ask for short options) on the Primary Market, or if there are no such sales, at the average of the most recent bid and asked quotations on such

Notes to Financial Statements (Unaudited) (continued)

Primary Market, or if such quotations are not available, at the last bid quotation (in the case of purchased options) or the last asked quotation (in the case of written options). If, however, there are no such quotations, such options will be valued using the implied volatilities observed for similar options or from aggregated data as an input to a model. Options traded in the over-the-counter market, if any, are valued at the price communicated by the counterparty to the option, which typically is the price at which the counterparty would close out the transaction. Option contracts, if any, that are neither exchange-listed nor traded in the over-the-counter market, and where no broker can provide a quote or approved pricing vendor a price, may be valued using the implied volatilities observed for similar instruments or from aggregated market data received from services (e.g., Bloomberg) as an input to a widely accepted model.

The Fund is permitted to invest in investments that do not have readily available market quotations. For such investments, the Act requires the Board to determine their Fair Value. The aggregate value of these investments amounted to \$2,484,228, or 1.70% of the Fund's net assets at June 30, 2021 and are listed in Note 3 to the Schedule of Investments.

Various inputs are used to determine the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1—unadjusted quoted prices in active markets for identical assets and liabilities

Level 2—other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)

Level 3—significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of June 30, 2021:

	Level 1 Quoted Prices	Level 2 Other Significant Observable Inputs	Level 3 Significant Unobservable Inputs	Investments Valued at NAV**	Total
Investments in Securities*					
Common Stock	\$138,773,674	\$ —	\$1,401,408	\$ —	\$140,175,082
Preferred Stock	—	—	48,767	—	48,767
Limited Partnership	—	—	—	1,034,053	1,034,053
Money Market Deposit Account	—	985,270	—	—	985,270
Total Investments in Securities	<u>\$138,773,674</u>	<u>\$985,270</u>	<u>\$1,450,175</u>	<u>\$1,034,053</u>	<u>\$142,243,172</u>

* Please see the Schedule of Investments for industry classifications.

** As of June 30, 2021, certain of the Fund's investments were valued using net asset value ("NAV") per share (or its equivalent) as a practical expedient for fair value and have been excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented in the statement of assets and liabilities.

Notes to Financial Statements (Unaudited) (continued)

The Fund values its investment in a private equity limited partnership in accordance with Accounting Standards Codification 820-10-35, "Investments in Certain Entities that Calculate Net Asset Value Per Share (Or its Equivalent)" ("ASC 820-10-35"). ASC 820-10-35 permits a reporting entity to measure the fair value of an investment that does not have a readily determinable fair value, based on the NAV of the investment as a practical expedient, without further adjustment, unless it is probable that the investment will be sold at a value significantly different than the NAV. If the NAV of the investment is not as of the Fund's measurement date, then the NAV should be adjusted to reflect any significant events that may change the valuation. Inputs and valuation techniques for these adjustments may include fair valuations of the partnership and its portfolio holdings provided by the partnership's general partner or manager, other available information about the partnership's portfolio holdings, values obtained on redemption from other limited partners, discussions with the partnership's general partner or manager and/or other limited partners and comparisons of previously-obtained estimates to the partnership's audited financial statements. In using the unadjusted NAV as a practical expedient, certain attributes of the investment that may impact its fair value are not considered. Attributes of those investments include the investment strategies of the privately held companies and may also include, but are not limited to, restrictions on the investor's ability to redeem its investments at the measurement date and any unfunded commitments.

Inputs and valuation techniques used by the Fund to value its Level 3 investments in privately-held companies may include the following: acquisition cost; fundamental analytical data; discounted cash flow analysis; nature and duration of restrictions on disposition of the investment; public trading of similar securities of similar issuers; economic outlook and condition of the industry in which the issuer participates; financial condition of the issuer; and the issuer's prospects, including any recent or potential management or capital structure changes. Although these valuation inputs may be observable in the marketplace as is characteristic of Level 2 investments, the privately-held companies, categorized as Level 3 investments, generally are highly illiquid in terms of resale.

When valuing Level 3 investments, management also may consider potential events that could have a material impact on the operations of a privately-held company. Not all of these factors may be considered or available, and other relevant factors may be considered on an investment-by-investment basis. The table below summarizes the techniques and unobservable inputs for the valuation of Level 3 investments.

THE SWISS HELVETIA FUND, INC.

Notes to Financial Statements (Unaudited) (continued)

Quantitative Information about certain Level 3 Fair Value Measurements

	Fair Value at June 30, 2021	Valuation Technique	Unobservable Inputs	Range ¹
<i>Healthcare-Products</i>				
EyeSense AG, Series A—Common Shares	\$ 46,131	Market approach	Latest round of financing with an additional discount as a going concern using a probability weighted approach	70-90%
Spineart SA—Common Shares	1,355,277	Market approach		
<i>Industrial Goods & Services</i>				
SelfFrag AG Class A—Preferred Shares	48,767	Market approach	Latest round of financing with an additional discount as a going concern	40-60%
Total	\$1,450,175			

¹ Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. A change in the discount rate is accompanied by a directionally opposite change in fair value.

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

	Common Stock	Preferred Stock	Total
Balance as of December 31, 2020	\$1,465,458	\$ 59,168	\$1,524,626
Change in Unrealized Appreciation/Depreciation (a)	(64,050)	2,241,741	2,177,691
Net Realized Gain (Loss)	3,881	(2,230,260)	(2,226,379)
Gross Purchases	—	—	—
Gross Sales	(3,881)	(21,882)	(25,763)
Transfer out of Level 3	—	—	—
Balance as of June 30, 2021	<u>\$1,401,408</u>	<u>\$ 48,767</u>	<u>\$1,450,175</u>

^(a) The noted amounts of change in unrealized appreciation/depreciation relate to the fair value of Level 3 assets held on June 30, 2021.

C. Derivative Instruments

GAAP requires enhanced disclosure that enables investors to understand how and why an entity uses derivatives, how derivatives are accounted for, and how derivative instruments affect an entity's results of operations and financial position.

Notes to Financial Statements (Unaudited) (continued)

The Fund did not hold any derivative instruments as of June 30, 2021.

The effect of derivative instruments on the Statement of Operations for the six months ended June 30, 2021:

	Amount of Realized Gain on Derivatives Recognized in Income	
<u>Derivatives not accounted for as hedging instruments</u>	<u>Statement of Operations Location</u>	<u>Value</u>
Equity Contracts – Warrants	Net Realized Gain on Investments	\$ 37,567
	Change in Unrealized Depreciation on Derivatives Recognized in Income	
<u>Derivatives not accounted for as hedging instruments</u>	<u>Statement of Operations Location</u>	<u>Total</u>
Equity Contracts – Warrants	Net change in unrealized depreciation of investments	\$(30,339)

The average monthly share amount of warrants during the period January 1, 2021 – January 31, 2021 was 116,600. The average monthly market value of warrants during the period January 1, 2021 – January 31, 2021 was \$38,010.

D. Securities Transactions and Investment Income

Securities transactions are recorded on the trade date. Realized gains and losses are determined by comparing the proceeds of a sale or the cost of a purchase to a specific offsetting transaction.

Dividend income, net of any foreign taxes withheld, is recorded on the ex-dividend date. Interest income, including amortization of premium and accretion of discount, is accrued daily. Estimated expenses are also accrued daily.

The Fund records Swiss withholding tax as a reduction of dividend income, net of any amount reclaimable from Swiss tax authorities in accordance with the tax treaty between the United States and Switzerland.

Distributions received from securities that represent a return of capital or capital gains are recorded as a reduction of cost of investment and/or as a realized gain.

E. Distributions

The Fund pays dividends at least annually to the extent it has any federally taxable net investment income and makes distributions of any net realized capital gains to the extent that they exceed any capital loss carryforwards. The Fund determines the size and nature of these distributions in accordance with provisions of the Internal Revenue Code of 1986, as amended (the “Code”). The Fund records dividends and distributions on the ex-dividend date.

In May 2018, the Board adopted a managed distribution policy that permits the Fund to distribute long-term capital gains more frequently than once per year as permitted by the Act. Distributions under the managed distribution plan may consist of net investment income, net realized short-term capital gains, net realized long-term capital gains and, to the extent necessary, return of capital (or other capital sources). In August 2018, the Board suspended until further notice any distributions that would otherwise be payable pursuant to the managed distribution policy. In November 2019, the Board approved the

Notes to Financial Statements (Unaudited) (continued)

resumption of distributions pursuant to the managed distribution policy. The Board may change or terminate the managed distribution policy at any time without prior notice to Fund stockholders, which could have an adverse effect on the market price of the Fund's shares. On March 31, 2021 and June 30, 2021, in accordance with the Fund's managed distribution policy as then in effect, the Fund paid quarterly distributions of \$0.13755 per share of the Fund's common stock to all stockholders of record as of March 22, 2021 and June 21, 2021, respectively.

F. Federal Income Taxes

The Fund's policy is to continue to comply with the requirements of the Code that are applicable to regulated investment companies and to distribute all its taxable income to its stockholders. Therefore, no federal income tax provision is required.

Income and capital gain distributions are determined in accordance with federal income tax regulations, which may differ from GAAP. See Note 5 for federal income tax treatment of foreign currency gains/losses.

Management has analyzed the Fund's tax positions taken on federal income tax returns for all open tax years and has concluded that no provision for federal income tax is required in the Fund's financial statements. The Fund files federal tax returns which remain open for examination generally for the current year and the three prior years. In addition, the Fund holds investments in Switzerland and other foreign tax jurisdictions. Withholding taxes on foreign interest and dividends have been provided for in accordance with each applicable country's tax rules and rates.

G. Foreign Currency Translation

The Fund maintains its accounting records in U.S. dollars. The Fund's assets are invested primarily in Swiss equities. In addition, the Fund can make its temporary investments in Swiss franc-denominated bank deposits, short-term debt securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund's NAV, however, is reported, and distributions from the Fund are made, in U.S. dollars, resulting in gain or loss from currency conversions in the ordinary course of business. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. The cost basis of foreign denominated assets and liabilities is determined on the date that they are first recorded within the Fund and translated to U.S. dollars. These assets and liabilities are subsequently valued each day at prevailing exchange rates. The difference between the original cost and current value denominated in U.S. dollars is recorded as unrealized foreign currency gain/loss. In valuing securities transactions, the receipt of income and the payment of expenses, the Fund uses the prevailing exchange rate on the transaction date.

Net realized and unrealized gains and losses on foreign currency shown in the Fund's financial statements result from the sale of foreign currencies, from currency gains or losses realized between the trade and settlement dates of securities transactions, and from the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the Fund's books and the U.S. dollar equivalent of the amounts actually received or paid.

Notes to Financial Statements (Unaudited) (continued)

When calculating realized and unrealized gains or losses on investments, the Fund does not separate the gain or loss attributable to changes in the foreign currency price of the security from the gain or loss attributable to the change in the U.S. dollar value of the foreign currency. Other foreign currency translations resulting in realized and unrealized gain or loss are disclosed separately.

H. Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates.

I. Concentration of Market Risk

The Fund primarily invests in securities of Swiss issuers. Such investments may carry certain risks not ordinarily associated with investments in securities of U.S. issuers. These risks include future political and economic developments, unfavorable movements in the Swiss franc relative to the U.S. dollar, and the possible imposition of exchange controls and changes in governmental law and restrictions. In addition, concentrations of investments in securities of issuers located in a specific region expose the Fund to the economic and government policies of that region and may increase risk compared to a fund whose investments are more diversified.

Note 2—Fees and Transactions with Affiliates

Schroder Investment Management North America Inc. ("SIMNA") and its affiliate, Schroder Investment Management North America Limited ("SIMNA Ltd" and together with SIMNA, "Schroders"), serve as the Fund's investment adviser and investment sub-adviser, respectively. The Fund pays SIMNA an annual advisory fee of 0.70% of the Fund's average month-end net assets up to \$250 million, 0.60% of such assets in excess of \$250 million and up to \$350 million, 0.55% of such assets in excess of \$350 million and up to \$450 million, 0.50% of such assets in excess of \$450 million and up to \$550 million, and 0.45% of such assets in excess of \$550 million. As compensation for its investment sub-advisory services, SIMNA Ltd receives 58.5% of the advisory fee paid by the Fund to SIMNA.

The Fund pays each Director who is not an "interested person" (as such term is defined in the Act) of the Fund or Schroders ("Non-Interested Directors"), \$42,000 annually in compensation, except for the Chairman of the Board to whom the Fund pays an annual fee of \$56,000 and for the Chairs of the Audit, the Pricing and the Governance/Nominating Committees to each of whom the Fund pays an annual fee of \$48,000. In addition, the Fund pays each Non-Interested Director \$2,000 for each Board meeting attended in person, and \$750 for each Board meeting attended by telephone. Each Director who is a member of a Committee will be paid a fee of \$750 for each Committee meeting attended, whether in person or by telephone. The Board or a Committee may establish ad hoc committees or subcommittees. Any Committee or sub-committee member may be compensated by the Fund for incremental work outside of the regular meeting process based on the value

Notes to Financial Statements (Unaudited) (continued)

determined to be added to the Fund. In July 2018, the Board approved a change to its By-Laws and Board committee charters to provide that each Director who is not an “interested person” of Schroders or its affiliates will be entitled to receive the above fees.

Note 3—Other Service Providers

American Stock Transfer & Trust Company is the Fund’s transfer agent. U.S. Bank, N.A. serves as the Fund’s custodian and U.S. Bancorp Fund Services, LLC, doing business as U.S. Bank Global Fund Services, provides administration and portfolio accounting services to the Fund. The Fund pays these service providers’ fees, which are accrued daily and paid monthly.

In addition to its other service provider fees, the Fund incurs certain professional fees, including fees of its outside legal counsel as well as fees of its independent registered public accounting firm. Those fees vary depending on the nature of the Fund’s activities each year.

Note 4—Capital Share Transactions

The Fund is authorized to issue up to 50 million shares of capital stock. Transactions in capital shares were as follows:

	For the Six Months Ended June 30, 2021		For the Year Ended December 31, 2020	
	Shares	Amount	Shares	Amount
Dividends Reinvested	—	\$ —	—	\$ —
Repurchased through Stock Repurchase Program (Note 6)	—	(125)*	(54,857)	(449,102)
Repurchased from Tender Offer (Note 7)	—	—	—	—
Net Increase/(Decrease)	—	\$(125)	(54,857)	\$(449,102)

* Represents a Deposit/Withdrawal At Custodian (DWAC) fee assessed in the current fiscal year with respect to prior year stock repurchases.

Note 5—Federal Income Tax and Investment Transactions

The tax character of distributions paid during 2020 and 2019 were as follows:

	2020	2019
Ordinary Income	\$1,066,099	\$1,656,554
Return of Capital	6,332,807	—
Long-Term Capital Gains	—	206,149
Total	\$7,398,906	\$1,862,703

Under current tax law, capital losses and specified ordinary losses realized after October 31 may be deferred and treated as occurring on the first business day of the following fiscal year. The Fund did not defer any post-October capital and currency losses and other late-year deferrals for the fiscal year ended December 31, 2020.

Capital loss carryovers retain their character as either long-term capital losses or short-term capital losses and are applied as a new loss on the first day of the immediately succeeding tax year. During the tax year ending December 31, 2020, the Fund had a short-term capital loss carryover of \$13,218 and a long-term capital loss carryover of \$2,562,930.

THE SWISS HELVETIA FUND, INC.

Notes to Financial Statements (Unaudited) (continued)

At December 31, 2020, the components of distributable earnings on a tax basis were as follows:

Undistributed Ordinary Income	\$ —
Capital Loss Carry Forward	(2,576,148)
Current Late-Year Loss Deferral and Post-October Losses	—
Other Accumulated Gain (Loss)	(21,189)
Net Unrealized Appreciation (Depreciation)	39,021,432
Total	<u>\$36,424,095</u>

The differences between book basis and tax basis distributable earnings are primarily attributable to tax deferral of wash sales and investments in partnerships.

Gains and losses from foreign currency transactions are treated as ordinary income and loss, respectively, for federal income tax purposes.

The following summarizes all distributions declared by the Fund during the year ended December 31, 2020:

<u>Record Date</u>	<u>Payable Date</u>	<u>Ordinary Income</u>	<u>Return of Capital</u>	<u>Total Distribution</u>
3/23/20	3/31/20	\$0.02023006	\$0.12016994	\$0.14040
6/22/20	6/29/20	0.02023006	0.12016994	0.14040
9/21/20	9/30/20	0.02023006	0.12016994	0.14040
12/21/20	12/31/20	0.01981941	0.11773059	<u>0.13755</u>
				<u>\$0.55875</u>

On the statements of assets and liabilities, the following adjustments were made for permanent tax adjustment:

Total Distributable Earnings	\$ 4
Paid In Capital	\$(4)

Note 6—Stock Repurchase Program

Pursuant to authorization by the Board, the Fund began open market purchases of its common stock on the New York Stock Exchange in 1999. The Board has authorized a stock repurchase program permitting such purchases by the Fund in each subsequent year, except for 2014. The principal purpose of the stock repurchase program has been to enhance stockholder value by increasing the Fund's NAV per share.

On December 7, 2018, the Fund announced the Board's approval of the Fund's stock repurchase program for 2019. Under the program, the Fund is authorized to make open-market repurchases of its common stock of up to 250,000 shares. The Fund did not repurchase any common stock pursuant to the program during the year ended December 31, 2019. On December 13, 2019, the Fund announced the Board's approval of the Fund's stock repurchase plan for 2020 of up to 250,000 shares of common stock. During the year ended December 31, 2020, the Fund repurchased 54,857 shares of its capital stock in the open market at a cost of \$449,102. The weighted average discount of these purchases comparing the average purchase price to net asset value at the close of the New York Stock Exchange was 16.33%.

Notes to Financial Statements (Unaudited) (continued)

On December 12, 2020, the Board approved the Fund's stock repurchase plan for 2021 of up to 250,000 shares of common stock. The Fund intends to repurchase shares of its common stock, at such times and in such amounts as is deemed advisable and in accordance with applicable law, subject to various factors, including the limitations imposed by the federal securities laws governing the repurchase of an issuer's stock by the issuer and the Fund's available cash to repurchase shares of the Fund's common stock in a tax-efficient manner.

Note 7—Tender Offer

On November 20, 2018, the Fund accepted for cash purchase 24,638,918 shares of the Fund's common stock at a price equal to \$7.86 per share, which represented 98% of the Fund's NAV per share of \$8.02 as of the close of the regular trading session of the New York Stock Exchange on November 19, 2018. As a result of the purchase of the 24,638,918 shares, the Fund had 13,267,111 shares of common stock outstanding.

Note 8—Capital Commitments

As of June 30, 2021, the Fund maintains an illiquid investment in one private equity limited partnership. This investment appears in the Fund's Schedule of Investments. The Fund's capital commitment for this partnership is shown in the table below:

<u>Investments</u>	<u>Original Capital Commitment*</u>	<u>Unfunded Commitment*</u>
Private Equity Limited Partnership—International^(a)		
Aravis Biotech II, Limited Partnership	\$3,515,984	\$ —

* *The original capital commitment represents 3,250,000 Swiss francs, which has been fully funded as of June 30, 2021. The Swiss franc/U.S. dollar exchange rate as of June 30, 2021 was used for conversion and equaled 0.92435 as of such date.*

^(a) *This category consists of one private equity limited partnership that invests primarily in venture capital companies in the biotechnology and medical technology sectors. There is no redemption right for the interest in this limited partnership. Instead, the nature of investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.*

Note 9—Investment Transactions

The aggregate cost of purchases and proceeds from sales of investments, other than short-term obligations, for the six months ended June 30, 2021 were \$7,560,996 and \$12,604,086, respectively.

Note 10—Subsequent Events

The Fund has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date financial statements were available to be issued. Based on this evaluation, no adjustments or additional disclosures were deemed to be required to the financial statements as of June 30, 2021.

Additional Information (Unaudited)

This report is sent to the stockholders of the Fund for their information. It is not a prospectus, circular or representation intended for use in the purchase or sale of shares of the Fund or of any securities mentioned in this report.

Proxy Voting Information

A description of the policies and procedures that the Fund uses to determine how to vote proxies relating to portfolio securities is available, without charge and upon request, by calling (800) 730-2932 and on the SEC's website at <http://www.sec.gov>. The Fund's proxy voting record for the twelve-month period ended June 30 is available, without charge and upon request, by calling (800) 730-2932 and on the SEC's website at <http://www.sec.gov>.

Availability of Quarterly Portfolio Schedules

The Fund files its complete schedule of portfolio holdings with the SEC for the first and third quarters of each fiscal year on Part F of Form N-PORT. The Fund's Part F of Form N-PORT are available on the SEC's website at <http://www.sec.gov>.

Code of Ethics

The Board of Directors of the Fund and the Advisor have adopted Codes of Ethics pursuant to Rule 17j-1 under the Act and Rule 204A-1 under the Investment Advisers Act of 1940, as amended the "Codes"). The Codes apply to the personal investing activities of various individuals including directors and officers of the Fund, the Fund's portfolio managers and designated officers, directors and employees of the Advisor. The provisions of the Codes place restrictions on individuals who are involved in managing the Fund's portfolio, who help

execute the portfolio managers' decisions or who come into possession of contemporaneous information concerning the investment activities of the Fund.

The fundamental principle of the Codes is that the individuals covered by the Codes have a fiduciary responsibility to the Fund and its stockholders. They are, therefore, required at all times to place the interests of the Fund and the stockholders first and to conduct all personal securities transactions in a manner so as to avoid any actual or potential conflict of interest or abuse of their position of trust.

Portfolio managers and other individuals, within the Advisor, with knowledge of Fund investment activities are prohibited from purchasing or selling a security during a blackout period of 30 calendar days before and after the date on which the Fund effects a trade in the same or a similar security. They are also prohibited from engaging in short-term trading of Swiss equity or equity-linked securities.

Additionally, the Fund's portfolio managers are prohibited from participating in any initial public offering or private placement of Swiss equity and equity-linked securities and other covered individuals must obtain prior clearance before doing so.

The Advisor's Code provides that any individual subject to such Code and who violates the provisions of the Code is required to reverse the transaction and to turn over any resulting profits to the Fund. The Fund and the Advisor have adopted compliance procedures and have appointed compliance officers to ensure that all covered individuals comply with the Codes.

Additional Information (Unaudited) (concluded)

Federal Tax Distribution Information

The Fund designates 100% of its ordinary income dividend distributions for the qualified dividend rate (QDI) as defined in Section 1(h)(11) of the Internal Revenue Code.

The amounts may differ from those elsewhere in this report because of difference between tax and financial reporting requirements. For federal income tax purposes, distributions from short-term capital gains are classified as ordinary income.

The Fund intends to elect to pass through to stockholders the income tax credit for taxes paid to foreign countries. Foreign source income and foreign tax expense per outstanding shares on December 31, 2020, were \$0.25 and \$0.03 per share, respectively.

Foreign Income Information

Pursuant to Section 853 of the Internal Revenue Code, the Fund designates the following amounts as foreign taxes paid for the year ended December 31, 2020. Foreign taxes paid for purposes of Section 853 may be less than actual foreign taxes paid for financial statement purposes.

<u>Gross Foreign Source Income</u>	<u>Foreign Taxes Pass-through</u>	<u>Gross Foreign Source Income Per Share</u>	<u>Foreign Taxes Pass-through Per Share</u>	<u>Shares Outstanding at 12/31/20</u>
\$3,277,765	\$443,710	\$0.24808523	\$0.03358322	13,212,254

Information Regarding Approval of Investment Advisory Agreement (Unaudited)

At a meeting via video conference held on March 12, 2021, all of the members of the Fund's Board of Directors who are not "interested persons" (as defined in the Investment Company Act of 1940, as amended) of the Fund (the "Independent Directors"), constituting a majority of the Fund's Board of Directors, considered and approved a proposal to renew (i) the Investment Advisory Agreement, dated as of April 17, 2014 (the "Advisory Agreement"), between the Fund and Schroder Investment Management North America Inc. ("SIMNA"), and (ii) the Sub-Advisory Agreement, dated as of April 17, 2014, as amended as of November 1, 2015, as of September 19, 2017 and as April 1, 2020 (the "Sub-Advisory Agreement" and, together with the Advisory Agreement, the "Agreements"), between SIMNA and Schroder Investment Management North America Limited ("SIMNA Ltd." and, together with SIMNA, the "Adviser"). Prior to the meeting, Fund counsel requested, and the Adviser provided, materials to aid the Directors in their consideration of the proposal. It was noted at the March 19, 2021 meeting that the meeting was being held by video conference notwithstanding the requirements of Section 15(c) of the Investment Company Act of 1940, as amended (the "Investment Company Act"), in reliance on exemptive relief provided by the Securities and Exchange Commission due to the Covid-19 pandemic. It was also noted that the Directors met over the course of the year with investment advisory personnel from the Adviser and regularly review detailed information regarding the Fund. In addition, the Board held a meeting via video conference on March 5, 2021 with counsel and

representatives of the Adviser to commence review of the materials provided and the relevant legal considerations. In approving the continuation of the Agreements, the Directors considered all factors that they considered relevant, including the specific factors described below. The Directors did not identify any one factor as all-important or controlling, and each Director attributed different weights to the various factors.

The Directors considered various data and information regarding the nature, extent and quality of services provided, including, among other things, information about the background and experience of senior management and investment personnel responsible for managing the Fund. The Directors considered the information provided regarding the portfolio managers and other resources dedicated to the Fund and the investment philosophy and process and disciplined investment approach followed by those individuals in managing the Fund, including the importance of dedicated Switzerland-based portfolio managers. The Directors considered that the Adviser's Chief Operating Officer was retiring at the end of May 2021 and was not being replaced and that his duties would be allocated as appropriate to the Adviser's existing management and received assurances that the Fund would continue to have access to management of the Adviser as and when needed.

The Directors reviewed the Fund's investment performance, determining that the Fund's performance should be evaluated against the achievement of the Fund's investment objective of seeking long-term capital

Information Regarding Approval of Investment Advisory Agreement (Unaudited)
(continued)

appreciation through investment primarily in equity and equity-linked securities of Swiss companies. The Directors considered the Fund's performance against the Swiss Performance Index (the "SPI") and against a list of non-U.S. funds that invest in Swiss equities in the Morningstar Category "Switzerland Large-Cap Equity (offshore territories)", which includes two non-U.S. funds advised by the Adviser. Although the performance data for funds included in the list included one-year, two-year, three-year, five-year and 10-year returns ended December 31, 2020, the Directors considered most relevant the total returns for the one-year, two-year, and five year periods ended December 31, 2020 due to the fact that the Adviser commenced management of the Fund effective July 1, 2014.

The Directors noted that the Fund's total return based on net asset value on an absolute basis was a strong 14.29% for the one year period ended December 31, 2020, and that its total return based on share price over that period was 14.18%, both outperforming the 13.83% increase in the SPI for the same period. The Directors also noted that for the period from January 1, 2015 through January 31, 2021, the Fund's total return based on share price underperformed the SPI by 7.47% while total return based on net asset value for that period underperformed the SPI by 15.34%. The Directors noted that for the two month period ended February 28, 2021, the Fund outperformed the SPI based on net asset value (0.99%) and based on share price (3.19%). The Directors also noted that the Fund outperformed the Adviser's non-U.S. peer funds on a total return share price basis for the

one-year, three-year and five-year periods ended December 31, 2020. The Directors also observed that, unlike the Fund, the returns of the SPI and the peer funds were not subject to the regulatory restrictions, including issuer and concentration limits, applicable to the Fund by virtue of the Investment Company Act.

The Directors reviewed the information provided by the Adviser and compiled by Broadridge showing a comparison of the Adviser's fee rate for the Fund, as well as the Fund's expense ratio, compared to a peer group of U.S. registered closed-end funds selected independently by Broadridge having similar objectives, strategies and asset sizes as the Fund. The Directors noted that the Fund ranked in the first quintile with respect to the Adviser's contractual fee, second quintile with respect to the Adviser's actual fee, fifth quintile with respect to the Fund's total expenses and fifth quintile with respect to the Fund's non-management expenses. The Directors considered that in November 2018 the Fund completed a large self-tender offer that reduced the size of the Fund and thereby increased expense ratios for the Fund commencing in 2019. The Directors considered that the peer non-U.S. funds advised by the Adviser had higher management fees compared to the Fund.

The Directors considered information regarding the profitability of the Fund's advisory arrangements to the Adviser. The Adviser discussed the methodology utilized for determining its profitability. The Directors determined that the level of profitability did not appear inappropriate or unreasonable at this time. The Directors noted that the Adviser

Information Regarding Approval of Investment Advisory Agreement (Unaudited) (concluded)

experienced an increase in profitability in 2020 compared to 2019 due to an increase in the amount of assets under management during the year. During 2020 the Fund had average net assets of \$126 million whereas during 2019 the Fund had average net assets of \$119 million.

The Directors considered that the Fund is a closed-end fund and that it was not expected to have meaningful asset growth absent primarily a rights offering or an acquisition. They did not view the potential for realization of economies of scale as the Fund's assets grow to be a meaningful factor in their deliberations, and that due to the Fund's significant tender offer completed in November 2018, it does not appear that the Fund will likely experience economies of scale in the near future. The Non-Interested Directors noted, however, that the advisory fee rate schedule under the Advisory Agreement contains multiple breakpoints commencing with assets of U.S. \$250 million and above and that these breakpoints would benefit stockholders.

The Directors considered information regarding the financial position of each of SIMNA and SIMNA Ltd. and were satisfied that they each have adequate resources to continue to perform the services required under the Agreements.

The Directors considered other benefits that the Adviser or its parent could be considered to derive from their relationship with the Fund, including the marketing value of the Fund's performance in attracting other clients. The Directors determined that these benefits were relatively minor and did not affect their overall assessment of the reasonableness of the relationship.

Based on the evaluation of these factors, the Board of Directors, including the Independent Directors, unanimously concluded that the Fund's advisory fee rate was reasonable in relation to the service rendered by the Adviser and, therefore, approved the continuation of the Agreements.

THE SWISS HELVETIA FUND, INC.

Certain Information Concerning Directors (Unaudited)

The following tables set forth certain information about each person currently serving as a Director of the Fund, including his or her beneficial ownership of Common Stock of the Fund. All information presented in the tables is as of June 30, 2021.

Name, Address ¹ & Age	Position(s) with Fund (Since)	Principal Occupation(s) During At Least The Past Five Years	Other Directorships Held By Director During At Least The Past Five Years
<i>Class I</i>			
Richard Dayan Age: 78	Director (2018); Member of the Audit Committee (2018); Member of the Governance/ Nominating Committee (2018)	President and owner of Cactus Trading since 1990	Trustee of High Income Securities Fund since 2018; Director of Emergent Capital, Inc. (formerly, Imperial Holdings, Inc.) until 2016
Moritz A. Sell Age: 53	Director (2017); Member and Chair of the Audit Committee (2017); Lead Independent Director (2018)	Principal, Edison Holdings GmbH; Senior Advisor, Markston International LLC; Director, Market Strategist and Head of Proprietary Trading (London Branch), Landesbank Berlin AG and Landesbank Berlin Holding AG (formerly, Bankgesellschaft Berlin AG) from 1996 to 2013	Trustee of High Income Securities Fund since 2018; Director of FAX (Aberdeen Asia Pacific Income Fund) and FCO (Aberdeen Global Income Fund) since 2018; Director of IAF (Aberdeen Australia Equity Fund) since 2004; Director of Aberdeen Greater China Fund until 2018; Chairman and Director of Aberdeen Singapore Fund until 2018
<i>Class II</i>			
Andrew Dakos* Age: 55	Director (2017) and Chairman (2018)	Partner, Bulldog Investors, LLP; Principal of the former general partner of several private investment partnerships in the Bulldog Investors group of private funds; Principal of the managing general partner of Bulldog Investors General Partnership	President and Director of Special Opportunities Fund, Inc. since 2009; Trustee, Crossroads Liquidating Trust (formerly, Crossroads Capital, Inc.) from 2015-2020; President and Trustee of High Income Securities Fund since 2018; Director, Brookfield DTLA Fund Office Trust Investor Inc. since 2017; Director, Emergent Capital, Inc. until 2017

* Mr. Dakos is considered an "interested person" of the Fund within the meaning of the 1940 Act (and a Class II Interested Director of the Fund) as a result of his position as President and Chief Executive Officer of the Fund.

THE SWISS HELVETIA FUND, INC.

Certain Information Concerning Directors (Unaudited) (concluded)

Name, Address ¹ & Age	Position(s) with Fund (Since)	Principal Occupation(s) During At Least The Past Five Years	Other Directorships Held By Director During At Least The Past Five Years
<i>Class III</i>			
Phillip F. Goldstein Age: 76	Director (2018); Member and Chair of the Governance/ Nominating Committee (2018)	Partner of Bulldog Investors, LLP since 2009; Principal of the former general partner of several private investment partnerships in the Bulldog Investors group of private funds since 2009	Chairman and Director of The Mexico Equity and Income Fund, Inc. since 2000; Chairman, Director and Secretary of Special Opportunities Fund, Inc. since 2009; Chairman and Secretary of High Income Securities Fund since 2018; Director of Brookfield DTLA Fund Office Trust Investor Inc. since 2017; MVC Capital, Inc. from 2012-2020; Trustee of Crossroads Liquidating Trust (formerly, Crossroads Capital, Inc.) from 2016-2020; Chairman and Director of Emergent Capital, Inc. (formerly, Imperial Holdings, Inc.) until 2017
Gerald Hellerman Age: 83	Director (2018); Member of the Audit Committee (2018); Member and Chair of the Pricing Committee (2018)	Chief Compliance Officer of The Mexico Equity and Income Fund, Inc. from 2001 through March 31, 2020 and Special Opportunities Fund, Inc. from 2009 through March 31, 2020; Managing Director of Hellerman Associates (a financial and corporate consulting firm) since 1993 (which terminated activities as of December 31, 2013)	Director of Mexico Equity and Income Fund, Inc. since 2001; Special Opportunities Fund, Inc. since 2009; MVC Capital, Inc. from 2003-2020; Trustee of Crossroads Liquidating Trust (formerly, Crossroads Capital, Inc.) from 2017-2020; Fiera Capital Series Trust since 2017; Trustee of High Income Securities Fund since 2018; Director of Emergent Capital, Inc. (formerly, Imperial Holdings, Inc.) until 2017; Ironsides Partners Opportunity Offshore Fund Ltd. until 2016

THE SWISS HELVETIA FUND, INC.

Certain Information Concerning Officers (Unaudited)

The following table sets forth certain information about each person serving as an Officer of the Fund as of June 30, 2021.

<i>Officers²</i>			
Name, Address ¹ & Age	Position(s) with Fund	Term of Office and Length of Time Served	Principal Occupation(s) During At Least The Past Five Years
Andrew Dakos Age: 55	President and Chief Executive Officer; Director and Chairman.	President and Chief Executive Officer since 2019; Chairman since 2018; Director since 2017	Partner, Bulldog Investors, LLP; Principal of the former general partner of several private investment partnerships in the Bulldog Investors group of private funds; Principal of the managing general partner of Bulldog Investors General Partnership
Thomas Antonucci Age: 52	Chief Financial Officer	Since 2019	Director of Operations, Bulldog Investors, LLP; Chief Financial Officer and Treasurer of Special Opportunities Fund; Treasurer of High Income Securities Fund
Stephanie Darling Age: 51	Chief Compliance Officer	Since 2019	General Counsel and Chief Compliance Officer of Bulldog Investors, LLP; Chief Compliance Officer of High Income Securities Fund, Special Opportunities Fund, Inc., and Mexico Equity and Income Fund, Inc.; Principal of The Law Office of Stephanie Darling; Editor-in-Chief of The Investment Lawyer
Rajeev Das Age: 52	Secretary	Since 2019	Head of Trading, Bulldog Investors, LLP

¹ The address for each Director and Executive Officer is c/o The Swiss Helvetia Fund, Inc., 615 East Michigan Street, Milwaukee, WI 53202.

² Each Executive Officer serves on a year-to-year basis for an indefinite term, until his or her successor is elected and qualified.

Automatic Dividend Reinvestment Plan (Unaudited)

Terms and Conditions

Pursuant to this Automatic Dividend Reinvestment Plan (the "Plan") of The Swiss Helvetia Fund, Inc. (the "Fund"), unless a holder (each, a "Shareholder") of the Fund's shares of common stock (the "Common Shares") otherwise elects, all income dividends, capital gain distributions and returns of capital, if any (collectively referred to herein as "dividends"), on such Shareholder's Common Shares will be automatically reinvested by American Stock Transfer & Trust Company, as agent for Shareholders in administering the Plan (the "Plan Administrator"), in additional Common Shares of the Fund. Shareholders who elect not to participate in the Plan will receive all dividends payable in cash directly to the Shareholder of record (or, if the Common Shares are held in street or other nominee name, then to such nominee) by American Stock Transfer & Trust Company LLC, as the Dividend Disbursing Agent. Shareholders may elect not to participate in the Plan and to receive all dividends in cash by contacting the Plan Administrator. Enrollment, purchase or sales of shares and other transactions or services offered by the Plan can be directed to the Plan Administrator through the following:

Telephone

Telephone the Plan Administrator: 1-888-556-0425.

In Writing

You may also write to the Plan Administrator at the following address: American Stock Transfer & Trust Company, PO Box 922, Wall Street Station, New York, NY 10269-0560. Be sure to include your name, address, daytime phone number, social security or tax I.D.

number and a reference to The Swiss Helvetia Fund, Inc. on all correspondence.

Participation in the Plan is completely voluntary and may be terminated at any time without penalty by providing notice in writing to the Plan Administrator at least 3 business days prior to any dividend payment date for that dividend to be payable in cash. A request for termination that is received less than 3 business days prior to any dividend payment date will be processed by the Plan Administrator, but you will have that dividend reinvested in additional Common Shares. However, all subsequent dividends will be payable in cash unless and until you resume participation in the Plan. To resume participation in the Plan, your request to enroll in the Plan must be received by the record date for that dividend distribution. If received after the record date, your participation in the Plan will begin with the next dividend declaration.

Whenever the Fund declares a dividend, payable either in Common Shares or in cash, participants in the Plan will receive a number of Common Shares determined in accordance with the following provisions and non-participants in the Plan will receive cash. The Common Shares will be acquired by the Plan Administrator for the participants' accounts, depending upon the circumstances described below, either: (i) through the receipt of additional unissued but authorized Common Shares from the Fund ("newly issued Common Shares") or (ii) by purchase of outstanding Common Shares on the open market ("open-market purchases") on the New York Stock Exchange, the primary national securities exchange on which the Common Shares are traded, or elsewhere.

Automatic Dividend Reinvestment Plan (Unaudited) (continued)

If, on the payment date for any dividend, the net asset value ("NAV") per Common Share is equal to or less than the market price per Common Share (plus estimated brokerage trading fees) (such condition being referred to herein as "market premium"), the Plan Administrator will invest the dividend amount in newly issued Common Shares on behalf of the participants. The number of newly issued Common Shares to be credited to each participant's account will be determined by dividing the dollar amount of the dividend by the NAV per Common Share on the date the Common Shares are issued, provided that, if the NAV per Common Share is less than or equal to 95% of the then current market price per Common Share on the date of issuance, the dollar amount of the dividend will be divided by 95% of the market price on the date of issuance for purposes of determining the number of shares issuable under the Plan.

If, on the payment date for any dividend, the NAV per Common Share is greater than the market price of the Common Shares (plus estimated brokerage trading fees) (such condition being referred to herein as "market discount"), the Plan Administrator will invest the dividend amount in Common Shares acquired on behalf of the participants in open-market purchases.

In the event of a market discount on the payment date for any dividend, the Plan Administrator will have until the last business day before the next date on which the Common Shares trade on an "ex-dividend" basis or in no event more than 30 days after the record date for such dividend, whichever is sooner (the "last purchase date"), to invest the

dividend amount in Common Shares acquired in open-market purchases. If, before the Plan Administrator has completed its open-market purchases, the market price of a Common Share exceeds the NAV per Common Share, the average per Common Share purchase price paid by the Plan Administrator may exceed the NAV of the Common Shares, resulting in the acquisition of fewer Common Shares than if the dividend had been paid in newly issued Common Shares on the dividend payment date. Because of the foregoing difficulty with respect to open-market purchases, if the Plan Administrator is unable to invest the full dividend amount in open-market purchases during the purchase period or if the market discount shifts to a market premium during the purchase period, the Plan Administrator may cease making open-market purchases and may invest the uninvested portion of the dividend amount in newly issued Common Shares at the NAV per Common Share at the close of business on the last purchase date provided that, if the NAV is less than or equal to 95% of the then current market price per Common Share, the dollar amount of the dividend will be divided by 95% of the market price on the date of issuance for purposes of determining the number of Common Shares issuable under the Plan.

The Plan Administrator maintains all registered Shareholders' accounts in the Plan and furnishes written confirmation of all transactions in the accounts, including information needed by Shareholders for tax records. Common Shares in the account of each Plan participant generally will be held by the Plan Administrator in non-certificated form

Automatic Dividend Reinvestment Plan (Unaudited) (continued)

in the name of the Plan participant, although the Plan Administrator will issue certificates for whole Common Shares upon your request. Certificates for fractional Common Shares will not be issued.

In the case of Shareholders such as banks, brokers or nominees that hold Common Shares for others who are the beneficial owners, the Plan Administrator will administer the Plan on the basis of the number of Common Shares certified from time to time by the record Shareholder and held for the account of beneficial owners who participate in the Plan.

There will be no brokerage charges with respect to Common Shares issued directly by the Fund as a result of dividends payable either in Common Shares or in cash. However, each participant will pay a pro rata share of brokerage trading fees incurred with respect to the Plan Administrator's open-market purchases of Common Shares in connection with the reinvestment of dividends under the Plan.

Participants in the Plan may sell any or all of their Common Shares in their Plan accounts by contacting the Plan Administrator. The Plan Administrator currently charges \$15.00 for the transaction, plus \$0.10 per Common Share for this service. Participants also may withdraw their Common Shares from their Plan accounts and sell those Common Shares through their broker.

Neither the Fund nor the Plan Administrator will provide any advice, make any recommendations, or offer any opinion with

respect to whether or not you should purchase or sell your Common Shares or otherwise participate in the Plan. You must make independent investment decisions based on your own judgment and research. The Common Shares held in Plan accounts are not subject to protection under the Securities Investor Protection Act of 1970.

Neither the Fund nor the Plan Administrator will be liable for any good faith act or for any good faith omission to act, including, without limitation, any claim or liability arising out of failure to terminate a participant's account upon the participant's death, the prices at which Common Shares are purchased or sold for a participant's account, the times when purchases or sales of Common Shares are made, or fluctuations in the market value of Common Shares. However, nothing contained in this provision affects a Shareholder's right to bring a cause of action based on alleged violations of the federal securities laws.

Voting

Each Shareholder proxy will include those Common Shares purchased or received pursuant to the Plan. The Plan Administrator will forward all proxy solicitation materials to participants and vote proxies for Common Shares held pursuant to the Plan in accordance with the instructions of the participants.

Taxation

The automatic reinvestment of dividends will not relieve participants of any federal, state or local income tax that may be payable (or required to be withheld) on such dividends.

Automatic Dividend Reinvestment Plan (Unaudited) (concluded)

Amendments to Plan

The Fund reserves the right to suspend, amend or terminate the Plan at any time. All Shareholders of record, both participants and non-participants in the Plan, will be notified of any suspension, termination or significant amendment of the Plan. If the Plan is terminated, Common Shares held in the participants' accounts will be distributed to the participants. Any change in the source of purchase of Common Shares under the Plan from open market purchases or direct issuance by the Plan Administrator does not constitute an amendment to the Plan.

Directors and Officers

Andrew Dakos <i>Chairman, President and Chief Executive Officer</i>	Gerald Hellerman ^{1,4} <i>Director</i>
Richard Dayan ^{1,5} <i>Director</i>	Thomas Antonucci <i>Chief Financial Officer</i>
Phillip Goldstein ² <i>Director</i>	Stephanie Darling <i>Chief Compliance Officer</i>
Moritz Sell ^{3,6} <i>Director</i>	Rajeev Das <i>Secretary</i>

¹ *Audit Committee Member*

² *Governance Nominating
Committee Chair*

³ *Audit Committee Chair*

⁴ *Pricing Committee Chair*

⁵ *Governance Committee
Member*

⁶ *Lead Independent Director*

Investment Adviser

Schroder Investment Management North America Inc.
7 Bryant Park
New York, NY 10018-3706
(800) 730-2932

Investment Sub-adviser

Schroder Investment Management North America Ltd.
1 London Wall Place
London, EC2Y, United Kingdom

Administrator

U.S. Bank Global Fund Services

Custodian

U.S. Bank, N.A.

Transfer Agent

American Stock Transfer & Trust Company
59 Maiden Lane
Plaza Level
New York, NY 10038
(888) 556-0425

Legal Counsel

Sullivan & Cromwell LLP

Independent Registered Public Accounting Firm

Tait, Weller & Baker LLP

The Investment Adviser

The Swiss Helvetia Fund, Inc. (the "Fund") is managed by Schroder Investment Management North America Inc. ("SIMNA Inc."). SIMNA Inc. is an investment adviser registered with the U.S. Securities & Exchange Commission (the "SEC"). It provides asset management products and services to a broad range of clients including Schroder Series Trust and Schroder Global Series Trust, investment companies registered with the SEC. SIMNA Inc. is part of a global asset management firm with approximately \$832.20 billion in assets under management and administration as of June 30, 2021.

Executive Offices

The Swiss Helvetia Fund, Inc.
615 East Michigan Street
Milwaukee, WI 53202
(800) 730-2932

For inquiries and reports:

(800) 730-2932

email: swzintermediary@schroders.com

Website Address

www.swzfund.com

The Fund

The Fund is a non-diversified, closed-end investment company whose objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.


The Fund is listed on the New York Stock Exchange under the symbol "SWZ".

Net Asset Value is calculated daily by 6:15 P.M. (Eastern Time). The most recent calculation is available by accessing the Fund's website www.swzfund.com. Net Asset Value is also published weekly in *Barron's*, the Monday edition of *The Wall Street Journal* and the Sunday edition of *The New York Times*.

[THIS PAGE INTENTIONALLY LEFT BLANK]

Schroders

The Swiss Helvetia Fund, Inc.
Executive Offices
615 East Michigan Street
Milwaukee, WI 53202
(800) 730-2932



A Swiss Investments Fund
www.swzfund.com

Semi-Annual Report

For the Six Months Ended
June 30, 2021

